Jelena Janjic created a nano-sized particle many years ago for use in treating cancer. But it was her own chronic pain that inspired her in 2011 to see if her particle could be used to treat pain, especially the chronic kind.
Nine years later it’s been working ideally.
Based on studies led by the Duquesne University pharmacologist and Duquesne biologist John Pollock, immune cells that consume her particles containing miniscule doses of a nonsteroidal anti-inflammatory drug were successfully blocked from generating pain and inflammation in rats. Single doses lasted about six days.
Similar success in future trials in humans could foretell a cure for chronic inflammatory pain and eliminate any need for opioid drugs that so readily cause addiction.
“It is very exciting and comes at the right time because it parallels findings in research — that there is a role for the immune system in treating chronic pain,” said Andrew Shepherd, an MD Anderson Cancer Center neuroimmunologist who had no involvement in the research. “It’s early and a lot of work still needs to be done but it has huge potential.”
Mrs. Janjic, who holds a Ph.D. in pharmaceutical sciences, said she doesn’t disclose her own diagnosis. But the studies show that her particle serves to manipulate large immune cells known as macrophages so they reduce rather than generate pain and inflammation.
In that way, the Janjic particle could represent a novel way of treating cancer, diabetes neuropathy and transplant rejection, among other conditions, Mrs. Janjic and other scientists say.
Early research also showed that the particles, which contain a near-infrared fluorescent compound and an MRI contrast, can be tracked to determine precise locations and inflammation intensity body-wide. That means the particles could be used in diagnostic scanning to locate inflammation body-wide for any condition including back pain and such elusive conditions as fibromyalgia.
“We now have a universal strategy, with surprisingly good results in pain, that the immune system can be manipulated to create the healing of any disease,” Mrs. Janjic said.
Because the process uses such low concentrations of drugs, toxicity would no longer be a factor, Mrs. Janjic said. “It doesn’t have toxic effects, period.”
Extinguishing pain
Pain is a function of the nervous system, said Mr. Pollock, who has been studying the nervous system for 30 years.
“Nerves throughout our bodies constantly are on the lookout for trouble — things that can cause damage to our tissues,” he said.
When tissue damage occurs, immune cells help to tell nerve cells (neurons) about it. Upon learning about the particle, Mr. Pollock said he realized it could be used to direct a pain remedy to the precise location of injury and source of pain, leading to his collaboration with Mrs. Janjic.
Her particle is a mere 140 nanometers in diameter, with one nanometer being one-billionth of a meter.
The nanoemulsion, as it is known, includes an oil mix, the fluorescent compound and celecoxib, the non-steroidal anti-inflammatory drug better known by its brand name Celebrex.
A common misconception is that the manipulated macrophage serves to transport then release the pain-relieving drug to the pain center. But the fact is, the particle never leaves the immune cell.
Its size ideally matches that of viruses and other micro-organisms that macrophages (the immune system’s “big eaters,” as their name suggests), routinely gobble up in the bloodstream en route to inflamed areas of injury and infection.
Typically, the macrophage’s goal is cleaning up the injured site while generating pain and inflammation, which serve important roles in the immune response. The National Institutes of Health, for example, describes inflammation as the immune system’s response to an irritant, with pain prompting the person or animal to take defensive action to prevent further damage.
Macrophages, about 150 times larger than the particle, have the initial role as an M1 cell (sometimes known as the bad immune cell) of activating high levels of the COX-2 enzyme to generate and release the pain-causing agent known as prostaglandin.
Once the M1 takes up the Janjic particle, the slow release of celecoxib (Celebrex) inside the macrophage inhibits COX-2 enzymes from producing prostaglandin, thus blocking pain and inflammation.
That action by the particle also forces the macrophage to transform into an M2 cell (the good immune cell). which reduces inflammation and pain and induces healing while causing other immune cells to do the same.
That entire process was exemplified successfully in studies involving rats and, more recently, mice. Now the Janjic-Pollock team has teamed with Dr. Vijay Gorantla at the Wake Forest Baptist Medical Center, to repeat the process in primates, with funding pending, and in the future, humans.
Success in humans would represent multiple advantages over traditional pain management.
• Oral and injected pain relievers require a large dose that must go body-wide with potential toxic impacts on certain organs. The particle uses a tiny dose that solely affect macrophages at the site of injury. That means only trace amounts of the drug will ever reach other organs.
• The Food and Drug Administration has found that Celebrex, a notably effective pain reliever, also poses a risk of serious cardiovascular impacts including clotting, heart attacks and strokes, along with the risk of adverse gastrointestinal effects. But the oral dose is 2,000-fold larger than the amount used in the Janjic particle — a dose small enough to eliminate such risks.
• The particle, due to the slowly dissolving nanoemulsion, remains inside the macrophage for the duration of the cell’s lifespan, allowing the single injected treatment to last from one week to a month, or longer.
• Given the dosage size that should succeed against any inflammatory pain, the treatment, if successful in humans, could altogether eliminate the need for opioids.
Results to date have prompted the research team to initiate studies to test whether the particle can eliminate pain from diabetic neuropathy and prevent transplant rejection, among other treatments.
Mrs. Janjic said she’s also working on a low-cost method of manufacturing the particle, with one dose requiring millions of them.
“It is complex in design but simple to produce,” she said of the particle.
Pain initiative
In 2011, Mrs. Janjic already had research underway to use her particle to transform macrophages into more efficient cancer killers. But she had no solid ideas about using it for pain.
For that reason, she invited fellow Duquesne professors including Mr. Pollock involved in any pain research to a luncheon to discuss how best to use her particle against pain. Eight professors showed up.
That meeting quickly resulted in an alliance between Ms. Janjic and Mr. Pollock, who proceeded to form the university’s Chronic Pain Research Consortium.
“I suggested that in putting pain medications in the [particle], we could see how well the drug reacted to pain in the nerves, with the medicine at just the site of injury that we were studying in my lab,” said Mr. Pollock, who holds a Ph.D. in biophysics. “There was synergy. She was doing the work with the nanoemulsion that incorporated celecoxib, a pain medicine, and I saw an interesting association with what I was doing.”
Soon after, they landed $100,000 in local funding, based on a quickly prepared white paper outlining how the particle could alter macrophages to treat pain. Since then, the research has landed funding from multiple arms of the National Institutes of Health and the National Science Foundation, among other sources.
Dr. Gorantla, former director of the reconstructive transplant program at UPMC, is currently an associate professor of surgery and director of the vascularized allotransplant program at Wake Forest Baptist.
He’s currently investigating nanomedicine strategies created in the Janjic lab to prevent transplanted organ rejection.
With standard-of-care pain management, he said, patients develop gradual tolerance for pain-killing drugs including opioids, requiring incrementally higher doses for effect, which can eventually lead to toxic levels and death.
With reference to the COVID-19 pandemic, Dr. Gorantla said that the nanomedicine holds further potential, as an oxygen carrier directly into cells, to better treat persistent hypoxia (lack of oxygen) that causes people to succumb to the disease.
“The opioid epidemic has underscored the need for novel treatments for acute and chronic pain,” Dr. Gorantla said. “Pain is a problem in all specialties of medicine, and I think this would be a big technology to invest in, given its safety and prolonged efficacy at extremely low doses.”
Mrs. Janjic, who gave a TEDxCMU talk on March 30, said the series of successful studies and advances in their research has taken 10 years but now is showing positive results.
“I knew how to create a nanoparticle for macrophages with all the components,” she said during a recent interview. “Then my getting sick, and inviting professors to lunch, and John showing up with pain experience, it all comes together.
“I can’t say I lay under tree and an apple fell on my head. But the design, this idea, is not just a delivery system, which always is the first impression — that macrophages deliver the drug. No, it’s the opposite, the particle changes the macrophage,” she said. “That’s the secret sauce.”
David Templeton: dtempleton@post-gazette.com or 724-809-4999.





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.